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Abstract
Tissue transglutaminase (TG2) is a multifunctional protein that binds to fibronectin and exerts protein transamidating
activity in the presence of Ca2+. We previously reported that TG2 is upregulated in ovarian tumors and enhances
intraperitoneal (i.p.) metastasis. TG2 is secreted abundantly in ovarian cancer (OC) ascites as an active enzyme, yet
its function in the extracellular compartment remains unknown. To study the distinct functions of secreted TG2, we
used recombinant His6-tagged TG2 and catalytically inactive enzyme in vitro and in vivo. By using i.p. and orthotopic
ovarian xenografts, we show that extracellular transglutaminase promoted OC peritoneal metastasis. The main path-
way activated by extracellular TG2was noncanonical nuclear factor-kappa B (NF-κB) signaling, and the enzymatic func-
tion of the proteinwas required to induce phosphorylation of IκB kinase α and processing of the precursor protein p100
into the active p52 subunit. A specific target of TG2-activated p52/RelB complex is the hyaluronan receptor, CD44.
Noncanonical NF-κB activation by extracellular TG2 induced CD44 up-regulation and epithelial-to-mesenchymal tran-
sition, contributing to increased cancer cell invasiveness and OC peritoneal dissemination. Taken together, our data
support that noncanonical NF-κB activation is the pathway through which extracellular TG2 promotes OC metastasis.
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Introduction
Tissue transglutaminase (TG2) is a multifunctional protein with enzy-
matic and nonenzymatic functions. As an enzyme, it regulates Ca2+-
dependent protein posttranslational modifications and cross-linking by
transferring acyl groups between glutamine and lysine residues [1]. Its
nonenzymatic functions include facilitation of cellular adhesion to the
extracellular matrix (ECM), particularly to fibronectin (FN) [2] and
GTPase activity, involved in transduction of α-adrenergic responses [3,4].
The functions of the protein are modulated by Ca2+ and guanosine-
5′-triphosphate (GTP) levels; high extracellular Ca2+ concentrations
enhance the enzymatic function, while high intracellular GTP
levels inhibit TGase activity [5]. This reciprocal activation of TG2
by Ca2+ and GTP causes structural allosteric changes affecting the
accessibility of the active site [6].
TG2 is overexpressed in breast, ovarian, brain, and pancreatic tu-
mors [7–9]; however, its roles in cancer are not fully elucidated. Several
reports, including ours, described TG2 as a protumorigenic protein that
enhances cellular invasion, metastasis, and chemoresistance [7–12].
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These functions have been attributed to activation of oncogenic signal-
ing, governed in part by the transcription factors nuclear factor-kappa B
(NF-κB) [11,13] and cyclic adenosine monophosphate response
element–binding protein (CREB) [14] and by the protein kinase B
(Akt) [15]. Direct activation of the NF-κB complex by intracellular
TG2 following the canonical pathway dependent on IκBα degradation
was demonstrated in pancreatic and ovarian cancer (OC) cells [11,13].
Indirect activation of serine/threonine kinase Akt and CREB in cancer
cells was attributed to TG2-mediated targeting of the phosphatases phos-
phatase and tensin homolog and protein phosphatase 2A [14,15]. By
regulating β-integrin–dependent cell adhesion to the matrix, TG2 also
engages outside-in cellular signaling through activation of the focal
adhesion kinase [9]. These processes contribute to increased cell survival
under stress and increased cell invasiveness [14,16,17]. However, TG2
is also secreted [18] and its role in the tumor milieu remains unknown,
being the subject of the current study.
In OC, the peritoneal space possesses unique characteristics that
protect cancer cells, facilitating proliferation and dissemination. Our
previous studies established that intracellular TG2 promotes OC me-
tastasis through enhancement of cell adhesion to the matrix [8] and
promotion of epithelial-to-mesenchymal transition (EMT) [17]. We
have also shown that TG2 is secreted in malignant ascites [8]; how-
ever, the function of TG2 in the extracellular compartment was never
investigated. By using anOC cell and xenograft model devoid of endog-
enous intracellular TG2 and recombinant catalytically active enzyme,
we now show that TG2 functioning in the extracellular milieu enhances
intraperitoneal (i.p.) metastasis. This was facilitated through activation
of NF-κB by TG2 through an IκBα-independent mechanism. Activa-
tion of the NF-κB complex by extracellular TG2 contributed to loss
of E-cadherin, increased cancer cell invasiveness, and up-regulation of
the hyaluronan receptor CD44. Taken together, our findings point to
a unique pathway, distinct from the mechanisms engaged by intracel-
lular TG2, through which the extracellular compartment of the enzyme
promotes OC peritoneal dissemination.
Materials and Methods
Cells
SKOV3 and OV90 cells were from the American Type Culture Col-
lection (ATCC, Manassas, VA) and cultured in growth media contain-
ing 1:1 MCDB 105 (Sigma, St Louis, MO) and M199 (Cellgro,
Manassas, VA). A2780 cells (Sigma) were grown in Dulbecco’s modi-
fied Eagle’s medium (Sigma). All treatments with recombinant protein
were carried out in the absence of FBS.
Expression and Purification of Human TG2
Full-length and catalytically inactive (C277A) TG2 were expressed
in Escherichia coli and purified as described [6], with minor modi-
fications (see Supplementary Materials). Purity of recombinant TG2
(rTG2) was confirmed by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE), and transamidation activity was
assayed using a colorimetric kit (Sigma; No. CS1070). Purified pro-
teins were endotoxin free, as measured by ToxinSensor Chromogenic
LAL Endotoxin Assay Kit (GeneScript, Piscataway, NJ).
Immunohistochemistry
Ninety-three de-identified paraffin-embedded OC specimens from
Pantomics Inc (Richmond, CA; tissue microarrays, n = 51) and from
the Indiana University (IU) Tissue Bank (Indianapolis, IN; n = 42)
were immunostained. Among the 42 specimens from the IU Tissue
Bank, 14 specimens included paired primary tumor and metastatic
peritoneal implants, with staining of the primary tumors being included
in the primary analysis. A secondary analysis compared TG2 staining in
primary versusmetastatic implants among the 14 pairs available. Immuno-
histochemistry (IHC) used a TG2 monoclonal antibody (Neomarkers,
Fremont, CA), at a dilution of 1:200 after sodium citrate antigen retrieval,
as previously described [8]. Secondary labeling used Avidin/Biotin
System (Dako, Carpinteria, CA). Negative controls omitting the primary
antibodywere run in parallel. Staining was graded from 0 (no staining) to
3+ (strong staining) by a board-certified pathologist (R.E.). Immuno-
reactivity was recorded if noted in more than 15% of tumor cells. The
IU Institutional Review Board approved the use of de-identified human
tissue specimens.
Malignant Ascites
Ten samples of OC ascites fluid cytologically positive and five sam-
ples of nonmalignant ascites (cirrhosis) were used.
Cell Transfections
Full-length TG2 subcloned in the retroviral vector pQCXIP was
transduced into OV90 cells, as described [17]. Pooled, stable clones
overexpressing TG2 were collected after puromycin selection. To
stably knock down TG2, the antisense construct AS-TG2 subcloned
into pcDNA3.1 was transfected into SKOV3 cells, as described [8].
Transient transfection of siRNA targeted RelB (Santa Cruz Biotech-
nology, Inc, Santa Cruz, CA) and CD44 (Dharmacon, Chicago, IL).
Scrambled siRNA was used as control.
I.p. and Orthotopic Ovarian Xenograft Model
Female nu/nu mice (7 weeks old) were from Harlan (Indianapolis,
IN). Studies were approved by the IU Institutional Animal Care and
Use Committee (IACUC) being in compliance with federal regulations.
For the i.p. xenograft model, 5 × 106 OV90 cells were injected i.p.
Two experiments were carried out, n = 8 per group and n = 6 per
group, with similar results. For the orthotopic ovarian model, ∼5 ×
105 OV90 cells diluted in 5 μl of media were injected under the
ovarian bursa (n = 4 per group), as described [17]. rTG2 or buffer
(control) was delivered three times per week i.p. at a dose of 2.5 μg
with the intent of reproducing concentrations of TG2 in the peritoneal
space of ∼1 μg/ml. An orthotopic ovarian xenograft experiment was
carried out using OV90 cells stably transduced with TG2 (n = 8) or
pQCXIP vector (n = 9). Five weeks after the i.p. or sub-bursal injection,
mice were killed, tumors were measured, and tumor volume was calcu-
lated as length ×width2/2.Miliary (disseminated) seeding was defined as
presence of >10 nodules (yes/no), and peritoneal metastatic implants
were counted.
Solid-phase Adhesion Assays
Cells were labeled with calcein (Molecular Probes, Eugene, OR) and
seeded at a density of 4 × 104 cells into 96-well plates precoated with
FN (5 μg/ml; Sigma), vitronectin (VN, 5 μg/ml; Sigma), collagen type 1
(10 μg/ml; Sigma), or BSA (1% wt/vol; Sigma). rTG2 was either
added to serum-free culture media or immobilized directly to the FN
matrix. rTG2 (20 μg/ml) immobilization to FN was performed as pre-
viously described [19]. All matrices were blocked with BSA (1%) for
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1 hour before cell seeding. After 60 minutes, adherent cells were quan-
tified in a fluorescence plate reader (Applied Biosystems, Grand Island,
NY). Experiments were performed in quadruplicate and repeated
at least twice. The neutralizing α5β1 antibody was from Millipore
(Billerica, MA).
Matrigel Invasion Assay
Invasion assay was performed by using two-dimensional (2D) cell
culture in a Matrigel matrix (BD Biosciences, Palo Alto, CA). Briefly,
2.5 × 104 cells treated or not treated with rTG2 (1 μg/ml) suspended
in 50 μl of cell culture media were seeded onto solidified Matrigel in
24-well plates as a monolayer (2D model). After incubation at 37°C,
invasive cells adhered to the surface of the gel and spread to form
networks (2D model). These were observed under an inverted micro-
scope and photographed live. The experiments were performed in
duplicates and repeated in independent conditions.
Western Blot Analysis
Cells were lysed in RIPA buffer containing protease inhibitors.
Nuclear and cytosolic fractions were separated by using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (NE-PER Kit; Pierce,
Rockford, IL) as per the manufacturer’s instructions. Equal amounts
of protein were separated by SDS-PAGE and blotted onto polyvinyl-
idene difluoride (PVDF) membranes (Millipore). Membranes were
probed with primary antibodies followed by HRP-conjugated second-
ary antibodies. Primary antibodies identified TG2 (Neomarkers), glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH; Meridian Life
Science, Cincinnati, OH), β-catenin (ECMBiosciences LLC,Versailles,
KY), IκBα (Santa Cruz Biotechnology, Inc), phosphorylated IκB
kinase α (pIKKα; Abcam, Cambridge, MA), E-cadherin, pP100,
pP65 (Ser536), p100/p52, Skp2, CD44, and RelB (Cell Signaling
Technology Inc, Danvers, MA). The antigen-antibody complexes
were visualized using enhanced chemiluminescence substrate (ECL;
Amersham Biosciences Corp, Piscataway, NJ). Densitometry analysis
used Gel-Pro Analyzer 3.1. Western blots were repeated at least twice.
Immunofluorescence
OV90 cells treated with rTG2, mutant rTG2, or control were plated
on FN-coated chamber slides (BD Biosciences). After fixation in 4%
paraformaldehyde, cells were permeabilized using 0.2% Triton X-100
in phosphate-buffered saline (15 minutes) and blocked for 1 hour with
3% goat serum in phosphate-buffered saline. Subsequently, cells were
incubated for 1 hour with E-cadherin antibody (1:200; Cell Signal-
ing Technology) followed by a 1-hour incubation with Alexa Fluor
488 anti-rabbit secondary antibody (Molecular Probes). Isotype-specific
IgG was negative control. Analysis used a Zeiss LSM 510 META
confocal multiphoton microscope system under UV excitation.
Quantitative Reverse Transcription–Polymerase
Chain Reaction
RNA extracted with RNA STAT-60 reagent (Tel-Test, Inc, Friends-
wood, TX) from cells or tumors was reverse transcribed using iScript
cDNA Synthesis Kit (Bio-Rad, Hercules, CA). FastStart TaqMan Probe
Master (Roche, Indianapolis, IN) was used for quantitative reverse
transcription–polymerase chain reaction (qRT-PCR) on an ABI Prism
7900 platform (Applied Biosystems), using specific primers and probes
(Table 1). RelativemRNA expression levels were normalized to GAPDH.
Data analysis used the comparative C t method [20].
Statistical Analysis
All values presented are means ± SE from duplicate (qRT-PCR,
Western blot analysis) or triplicate (solid-phase adhesion) experiments.
Comparisons between groups used the Student’s t test, with P values
< .05 being significant. IHC data were not normally distributed; there-
fore, correlation with histologic subtype, grade, and stage used the
nonparametric Kruskal-Wallis test. Pairwise tests were done using
exact Wilcoxon rank sum tests with P values adjusted by the Hochberg
step-up method.
Results
TG2 Expression in OC
Previously, we demonstrated that TG2 is expressed in a cancer-
restrictedmanner in ovarian tumors compared to normal surface ovarian
epithelium [8]. Here, we expanded those initial findings to a larger co-
hort of ovarian tumors (n = 93) and analyzed TG2 expression relative to
tumor stage, histologic grade, and type. The majority of samples in this
cohort were serous papillary (n = 47) and of high grade (n = 67; Table 2).
Both early (stages I–II, n = 50) and advanced stages (stages III–IV; n =
43) were analyzed. Most tumors displayed at least weak TG2 immuno-
staining (78 of 93), of which 68 (∼73%) stained 2+ or 3+ (Figure 1A).
Four specimens labeled as undifferentiated were excluded from the cor-
relationwith histology. TG2 expressionwas significantly correlated with
clear cell subtype versus others (P < .005) and with high-grade histology
versus others (P < .005) but not with Federation of Obstetricians and
Gynaecologists (FIGO) stage (Table 2).
TG2 Is Secreted in the Peritoneal Milieu
As OC disseminates in the peritoneal cavity, ascites containing
proteins secreted by tumor and mesothelial cells is generated [21–23].
Table 1. qRT-PCR Primers and TaqMan Probes.
Gene 5′ Primer 3′ Primer Probe
E-cadherin GCCGAGAGCTACACGTTCA GACCGGTGCAATCTTCAAA 80
GAPDH AGCCACATCGCTGAGACA GCCCAATACGACCAAATCC 60
Zeb-1 GCCAACAGACCAGACAGTGTT TCTTGCCCTTCCTTTCCTG 52
Zeb-2 AAGCCAGGGACAGATCAGC CCACACTCTGTGCATTTGAACT 68
Snail GCTGCAGGACTCTAATCCAGA ATCTCCGGAGGTGGGATG 11
CD44 CAACAACACAAATGGCTGGT CTGAGGTGTCTGTCTCTTTCATCT 40
Table 2. TG2 Expression by IHC in Ovarian Tumor Specimens.
Sample (n) TG2 Expression P Values
0–1+ 2+ 3+
Histologic type
Clear Cell 16 0 2 14 P < .005
Endometrioid 18 5 7 6 P = .43
Mucinous 8 2 6 0 P = .43
Serous 47 15 9 23 P = .43
Poorly differentiated 4 3 0 1 Excluded
Surgical stage
Stage I or II 50 11 12 27 P = .24
Stage III or IV 43 14 13 16 P = .24
Grade
Grades 1 and 2 22 7 14 1 P < .005
Grade 3 67 16 10 41 P < .005
Not available 4 2 0 2 Excluded
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Previously, we detected abundant TG2 in malignant OC ascites com-
pared to benign effusions [8]. Here, we estimated the concentration of
secreted TG2 by immunoblot analysis of ascites specimens compared
to known concentrations of purified protein. TG2 was detectable in
all malignant samples (n = 10), at concentrations estimated between
0.1 and 10 μg/ml (Figure 1B and TableW1), but not in fluid from non-
malignant disease (n = 5).
The objective of the subsequent studies was to investigate the
role of secreted TG2 in the peritoneal (extracellular) space. For this,
His6-tagged wild-type rTG2 and the mutant TG2 lacking enzymatic
activity (C277A, mTG2) were induced and purified on talon and anion
exchange columns, as previously described [24]. Protein purity was
>90% (Figure W1A) and enzymatic activity was comparable to com-
mercially available purified TG2, with the mutant TG2 lacking cross-
linking activity (Figure W1B). A2780 and OV90 cells not expressing
endogenously TG2 and SKOV3 cells stably transfected with an anti-
sense TG2 construct or control vector [8] were used. TG2 expression
level in these cells was measured by Western blot analysis (Figure 1C).
Extracellular TG2 Promotes Peritoneal Dissemination
To determine the role of secreted TG2 in metastasis, we used i.p.
and orthotopic ovarian xenografts derived fromOV90 cells. OV90 cells
were injected i.p. in nude mice and rTG2 was administered i.p. three
times per week at 2.5 μg per dose. Mice treated with rTG2 developed
disseminated metastatic implants on the omentum, mesentery, and
abdominal flanks compared to controls (Figure 2A). The average num-
ber of peritoneal implants in rTG2 and control-treated mice was 27.7 ±
5.2 versus 11.4 ± 3.4 (P < .017, n = 8 per group), but tumor volume was
not different (412 mm3 vs 578 mm3, P = .38; Figure 2, B and C).
We next used orthotopic ovarian xenografts, with OV90 cells in-
jected under the ovarian bursa and rTG2 administered i.p. The number
of peritoneal implants was increased in rTG2-treated mice versus controls
(31.7 vs 10.7, P = .002, n = 4 per group; Figure 2D), supporting that extra-
cellular TG2 promotes tumor dissemination. The mean volume of pri-
mary tumors was not significantly different, although there was a trend in
favor of rTG2-treated animals (730 mm3 vs 218.6 mm3, P = .07;
Figure 2E).
These data are consistent with effects observed when TG2 was
stably overexpressed in OV90 cells leading to its increased cellular
expression and secretion in conditioned medium (CM; Figure 2F ).
TG2 and vector-transduced OV90 cells implanted orthotopically
(n = 8 and 9, respectively) induced primary tumors of similar sizes
(1825 mm3 vs 1609 mm3, P = .6; Figure 2G ) but caused distinct
patterns of peritoneal dissemination. Specifically, eight of eight mice
injected with OV90-TG2 cells developed disseminated metastases
(>10 implants) compared to two of nine mice injected with control cells
(P = .002; Figure 2H), supporting the concept that increased cellular
TG2 expression level determines metastatic dissemination.
Interestingly, overexpression of TG2 did not affect cellular prolifer-
ation as measured by bromodeoxyuridine (BrdU; Figure W2, A and B)
Figure 1. TG2 is overexpressed in OC and secreted in malignant ascites. (A) Representative IHC for TG2; panel 1 (×100); panel 2 (×400);
panels 3 to 6 are matched primary ovarian tumors (left panels) and peritoneal implants (right panels, ×200, selected from n = 14 pairs).
(B) TG2 in OC and cirrhosis ascites. Western blot analysis for TG2 used titration standards with purified TG2 (10 to 1000 ng per lane). Ten
OC and five benign ascites specimens were loaded in equal volumes (30 μl). (C) Western blot analysis for TG2 in OC cell lines (OV90,
A2780, SKOV3, SKOV3-pcDNA3.1, and SKOV3-AS-TG2).
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or clonogenic assays (Figure W2C) under normal (10%) or low (1%)
serum conditions, consistent with the observed lack of association be-
tween TG2 expression and primary tumor size. Likewise, extracellular
TG2 did not affect OC cell proliferation. rTG2 added to low (1%)
or normal (10%) serum containing culture media failed to increase
OV90 cell proliferation (Figure W2, D and E).
Effects of Extracellular TG2 on Cell Adhesion to the Matrix
A necessary step in the establishment of peritoneal metastases
is adhesion to the ECM. We measured the effects of rTG2 to cell
adhesion to collagen, FN, and VN by using solid-phase adhesion
assays. TG2 overexpression in OV90 cells increased adhesion to FN
compared to control cells (Figure 3A; P < .05), consistent with pre-
vious findings that support TG2’s role stabilizing the β1-integrin/
FN complex [2,8,25]. However, rTG2 added to the culture media
(extracellular) did not alter adhesion to VN, collagen, or FN (Figure 3,
B–D). When cells were plated on FN surfaces pretreated with rTG2
(FN-rTG2), cell adhesion was increased by ∼20% compared to un-
treated FN (Figure 3E ). Interestingly, addition of C277A mutant
rTG2 to culture media or pretreatment of FN with enzymatically
inactive rTG2 did not affect cell adhesion (Figure 3E), suggesting that
catalytically active rTG2 is required for cell adhesion to FN-rTG2
matrix. Adhesion to TG2-coated FN matrix was blocked by preincu-
bation of cells with an anti–α5β1-integrin antibody (Figure 3F), sug-
gesting that it was mediated by β1-integrins. Collectively, these data
suggest that rTG2 added to the CM does not measurably alter cell
Figure 2. rTG2 promotes i.p. metastasis of OC xenografts. (A) OV90 cells injected i.p. generated tumors studding the mesentery.
I.p. administration of rTG2 increased peritoneal dissemination of OV90 cells in nude mice (right panel) compared to control-injected
mice (left panel). Arrows point to tumor deposits on the mesentery. Average number of tumor implants in the peritoneal space 5 weeks
after (B) i.p. (n = 8 mice per group) or (D) orthotopic ovarian (n = 4 mice per group) cancer cell implantation (P < .01). Average tumor
volume (mm3) ± SE 5 weeks after (C) i.p. or (E) orthotopic ovarian cancer cell implantation. (F) Western blot analysis for TG2 in OV90
cells stably transduced with empty vector and wild-type TG2 (upper panel) or in media conditioned by these cells (lower panel). (G) Mean
tumor volume ± SE generated from OV90-TG2 or control cells after orthotopic ovarian tumor implantation (n = 9 for control and n = 8 for
OV90-TG2). (H) Number of mice with military (disseminated) metastases (>10 peritoneal implants; P = .02).
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adhesion to the ECM but support the concept that cell adhesion is
increased when cells are plated on an FN matrix premodified by enzy-
matically active TG2.
Extracellular TG2 Induced OC Cell Invasiveness and
E-Cadherin Down-Regulation
To understand how extracellular TG2 affects metastasis, we mea-
sured its effects on cellular invasion, a necessary step for tumor dissem-
ination. For this, OC cells were cultured in Matrigel and treated with
rTG2 (72 hours). OV90 and A2780 that do not express TG2 grew
in cohesive, noninvading clumps. Treatment with rTG2 induced for-
mation of networks, indicative of an invasive phenotype (Figure 4A,
lower panels). SKOV3 cells that express TG2 and stably transfected
with vector or AS-TG2 [8,14] were used as a second model. Control
cells formed networks, whereas AS-TG2 cells remained clumped.
Treatment of AS-TG2 cells with rTG2 promoted invasion in Matrigel
similar to the phenotype of control cells (Figure 4A). The invasive
behavior corresponded to a mesenchymal phenotype appreciated by
phase-contrast microscopy. A2780 and OV90 cells treated with
rTG2 transitioned from epithelial, cobblestone to spindle-like mor-
phology consistent with rTG2-induced EMT (Figure 4A, right panels).
EMT was confirmed by quantifying epithelial and mesenchymal mark-
ers, E-cadherin, β-catenin, Snail-1, Zeb-1, and Zeb-2 at protein and
mRNA levels (Figure 4B). Cells treated with rTG2 expressed decreased
levels of E-cadherin and increased levels of β-catenin and transcriptional
repressor for E-cadherin (Zeb-1, Zeb-2, Snail). Treatment with rTG2
diminished E-cadherin expression in OV90 cells, as visualized by
immunofluorescence (Figure 4C ). However, treatment with the mu-
tant C277A recombinant protein did not affect E-cadherin expression
(Figure 4C), suggesting that the enzymatic activity of TG2 is necessary
for the induction of the mesenchymal phenotype.
Extracellular TG2 Activates the NF-κB Complex through a
Noncanonical Pathway
As NF-κB activation is a known inducer of EMT in TG2-expressing
cells [17,26], we measured whether rTG2 also activates the complex.
It is known that intracellular TG2 promotes degradation of IκBα,
causing activation of NF-κB through a canonical pathway [7]. In
contrast, extracellular TG2 did not measurably alter IκBα levels
(Figure 5A). However, rTG2 stimulation of OV90 cells caused phos-
phorylation of IKKα and p100 (Figure 5B). This corresponded to an
increase in p52, the transcriptionally active degradation fragment of
Figure 3. Effects of TG2 on cell adhesion to ECM proteins. (A) Adhesion to FN (5 μg/ml) of OV90-TG2 or pQCXIP-transduced cells.
(B) Adhesion of OV90 cells to VN-coated plates (5 μg/ml) in the presence of buffer or rTG2 (2.5 μg/ml) diluted in media. (C) Adhesion of
OV90 cells to collagen type 1–coated plates (10 μg/ml) in the presence of buffer or rTG2 (2.5 μg/ml) diluted in media. (D) Adhesion of OV90
cells to FN-coated plates (5 μg/ml) in the presence of buffer or rTG2 (2.5 μg/ml) diluted in media. (E) Adhesion of OV90 cells to FN-coated
plates (5 μg/ml) in the presence of rTG2 (1 μg/ml) or the enzymatically inactive C277A recombinant protein (1 μg/ml) either added to media
or used to pretreat the FN matrix. (F) Adhesion of OV90 cells to FN-coated plates (5 μg/ml) pretreated or not with rTG2 (20 μg/ml) in the
presence of α5β1-integrin neutralizing antibody (nAB, 1:100 dilution) or nonspecific IgG (control). Data represent average of four replicates
± SEM (*P < .05).
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p100 (Figure 5B). To understand whether the TG2 enzymatic func-
tion is important, active and catalytically inactive rTG2 were used.
Induction of p52 expression and phosphorylation of p65 and p100
were induced by wild-type TG2 but not by the C277A mutant (Fig-
ure 5C ), suggesting that TG2 enzymatic activity in the extracellular
space is necessary. Similar processing to p52 and phosphorylation of
p65 were observed in TG2-expressing SKOV3 cells and TG2-null
A2780 cells stimulated with rTG2 (Figure 5D), suggesting that the
observed effects are not cell type specific.
The final step in noncanonical NF-κB signaling is the formation
of the p52/RelB complex that translocates to the nucleus and activates
gene transcription. Treatment of OV90 and SKOV3 cells with
rTG2 caused increased RelB protein expression (Figure 5E , left and
middle panels), as well as RelB translocation to the nucleus (Figure 5E ,
right panel ).
Extracellular TG2 Downregulates E-cadherin through RelB
To assess the effects of TG2-induced NF-κB activation, we fo-
cused on two transcripts, CD44 and Skp-2, known to be inducible
by p52/RelB [27,28]. Both Skp-2 (Figure 6A) and CD44 (Figure 6B,
left panel ) were induced by rTG2 in OV90 cells. CD44 induction by
rTG2 was also demonstrated in SKOV3 and A2780 cells (Figure 6B,
middle and right panels).
To demonstrate that RelB is involved in rTG2-induced E-cadherin
repression and CD44 up-regulation, RelB was knocked down by
siRNA (Figure 6C , left panel ). R-TG2 inhibited E-cadherin expression
in SKOV3 cells transfected with scrambled siRNA (control) but not
in cells transfected with RelB siRNA (Figure 6C , middle panel ). RelB
knockdown also repressed basal levels of E-cadherin (Figure 6C ,middle
panel ). R-TG2 augmented CD44 expression in SKOV3 cells trans-
fected with scrambled siRNA (control) but not in cells in which RelB
was knocked down (Figure 6C , right panel ). Collectively, the data
demonstrate that regulation of E-cadherin and CD44 expression by
extracellular TG2 depends on RelB signaling.
As CD44 functions have been linked to EMT in other models
[29,30], we measured whether CD44 knockdown in OC cells altered
E-cadherin expression. CD44 was knocked down by siRNA (Fig-
ure 6D, left panel), and E-cadherin expression in response to rTG2
was measured by qRT-PCR. We observed increased E-cadherin ex-
pression in cells in which CD44 was silenced compared to siRNA
control–transfected cells (Figure 6D, right). Furthermore, rTG2-
induced E-cadherin down-regulation was prevented by CD44-targeted
siRNA, supporting that CD44 is a necessary element in this process.
To verify the functional significance of rTG2-induced CD44 in vivo,
the expression of the receptor was quantified by qRT-PCR in xenografts.
More than two-fold increased CD44 mRNA levels were observed in
Figure 4. Extracellular TG2 induces cell invasion and EMT. (A) Cell invasion in Matrigel using 2D cultures with A2780, OV90, and SKOV3/
pcDNA3.1 (control) or SKOV3/ASTG2 cells treated with buffer (upper panels, left) or rTG2 (1 μg/ml; lower panels, left) for 72 hours;
original magnification, ×100. Phase-contrast microscopy demonstrates cell morphology for A2780 and OV90 cells treated with control
or with rTG2 (1 μg/ml) for 7 days (original magnification, ×200; right panels). (B) Western blot analysis for E-cadherin and β-catenin for
control and rTG2 (1 μg/ml)–treated OV90 cells (72-hour treatment; left panel). Densitometry quantifies protein expression relative to
GAPDH. qRT-PCR quantifies expression levels for E-cadherin, Snail-1, Zeb-1, and Zeb-2 in OV90 cells treated with control and rTG2
(1 μg/ml) for 72 hours (right panel). Y axis represents fold change in gene expression levels normalized to GAPDH of rTG2-treated
OV90 cells compared with control (*P < .05). (C) Immunofluorescence staining for E-cadherin of OV90 cells treated with control,
rTG2, or mutant rTG2 (1 μg/ml) for 72 hours (×600).
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rTG2-treated tumors compared to controls, suggesting that the path-
way is relevant to induction of metastasis (Figure 6E). A model illus-
trating the distinct pathways activated by extracellular (shown here)
and intracellular TG2 (described previously and converging on Zeb-1,
[17]) to promote metastasis is presented in Figure 7.
Discussion
This is the first study analyzing the effects of extracellular TG2 on
the phenotype of OC cells in vitro and tumor formation and metas-
tasis in vivo. On the basis of clinical specimen–derived observations
that TG2 is secreted in the peritoneal milieu, our study demonstrates
that extracellular TG2 induces EMT and cancer cell invasiveness and
promotes peritoneal metastasis through a distinct pathway leading to
noncanonical activation of NF-κB.
Our findings that TG2 is expressed in more than 70% of ovarian
tumors are consistent with previous reports [8,31]. We also noted that
TG2 expression was increased in highly aggressive cancers (e.g., grade 3
and clear cell tumors), a novel observation. Although TG2 expres-
sion did not correlate with surgical stage, in some cases we observed
increased TG2 expression in metastatic implants compared to primary
tumors. Specifically, for 5 of 14 matched primary serous ovarian tu-
mors and omental metastases, we observed increased TG2 staining
in the metastatic implants compared to the primary tumors. In these
implants, TG2 immunostaining was more intense at the interface
with stroma, suggesting that the enzyme may be overexpressed at the
invasive front of tumors.
TG2 secretion in the ECM has remained an enigma, as the enzyme
lacks a signal recognition peptide that would target it to the endo-
plasmic reticulum. A recent study demonstrated that TG2 secretion
follows an unconventional pathway through recycling endosomes
where TG2 is packaged with internalized β1-integrins [32]. Indeed,
in this and in previous studies we detected abundant TG2 in CM
and in malignant ascites [8,14]. To demonstrate the distinct effects
of extracellular TG2, we used an OC cell model devoid of endogenous
TG2 and recombinant wild-type or mutant TG2. This model allowed
eliminating undue effects caused by the cellular compartment of the
enzyme. We targeted a concentration of extracellular TG2 of ∼1 μg/ml,
Figure 5. Extracellular TG2 activates noncanonical NF-κB signaling. (A) Western blot analysis for IκBα (upper panel) in OV90 cells treated
with rTG2 (1 μg/ml) for 15 to 45 minutes, under serum starvation. Stimulation with tumor necrosis factor–α (10 ng/ml) was used as a
positive control. (B) Western blot analysis for phospho-IκKα, phospho-p100, p100, and p52 in OV90 cells treated with rTG2 (1 μg/ml)
or BSA (control, 1 μg/ml). (C) Western blot analysis for phospho-p100, phospho-p65, p100, and p52 in OV90 cells treated with rTG2
(1 μg/ml) or catalytically inactive C277A rTG2 (1 μg/ml); line 4, untreated control. (D) Western blot analysis for phospho-p100 and phospho-
p65 and for p100 and p52 in SKOV3 (left panel) and A2780 (right panel) cells treated with rTG2 (1 μg/ml) for up to 6 hours. (E) Western
blot analysis for RelB in whole-cell lysates from OV90 (left panel) and SKOV3 cells (middle panel) or in nuclear extracts from OV90 cells
(right panel) treated with rTG2 (1 μg/ml) or control. Densitometry quantifies protein expression relative to GAPDH.
616 Extracellular TG2 in Ovarian Cancer Metastasis Yakubov et al. Neoplasia Vol. 15, No. 6, 2013
based on estimated TG2 concentrations in malignant ascites of
∼0.1 to 10 μg/ml, but we recognize high variability of TG2 secretion
in the peritoneal milieu. In a previous study, direct intratumoral in-
jection of TG2 at high concentration (200 μg) inhibited tumor growth
[33]. Those effects were attributed to TG2-induced alterations in the
ECM and, specifically, to increased deposition of collagen-1 [33]. Here,
we did not observe a significant effect of extracellular TG2 on tumor
size or OC cell proliferation but recorded increased number of metas-
tases, an end point previously not measured. We attribute the pro-
metastatic effects to the lower dose of TG2 used in our model. TG2
dose dependence has been previously demonstrated in a wound healing
model where angiogenesis was stimulated by low-dose TG2 (10–20 μg)
[34] and inhibited by higher concentrations (200 μg) [33].
The use of both i.p. and orthotopic ovarian xenograft models
strongly supports the effects of secreted TG2 on peritoneal dissemina-
tion. The orthotopic approach better mimics the phenomena of pri-
mary tumor formation and tumor spreading initiated from the primary
site compared to the i.p. model [35–37]. The demonstration that
in vitro rTG2 facilitates EMT and promotes cell invasion provides
further support to this concept. A limitation of our in vivo model is
that it does not completely eliminate the influence of host TG2, which
is present in small amounts in mesothelial cells lining the peritoneal
space. Interestingly, a previous study suggested that subcutaneous
tumor growth is enhanced in a TG2−/− background [33]; however,
the mechanism involved remained unclear. It is known that inflam-
matory responses are altered in TG2−/− animals, which display deficient
Figure 6. Extracellular TG2 activates noncanonical NF-κB signaling in OC cells. Western blot analysis for Skp2 (A) or CD44 (B) in OV90,
SKOV3, and A2780 cells treated with rTG2 (1 μg/ml). Densitometry quantifies protein expression relative to GAPDH. (C) Western blot
analysis for RelB in SKOV3 cells untransfected (UT) and transiently transfected with siRNA control or targeting RelB (left panel). qRT-PCR
quantifies E-cadherin (middle panel) or CD44 expression (right panel) in SKOV3 cells transiently transfected with siRNA control (si Ctl) or
targeting RelB and treated with rTG2 (1 μg/ml) or control for 18 and 72 hours. Y axis represents fold change in E-cadherin (middle panel)
or CD44 levels normalized to GAPDH in rTG2-treated cells compared with controls (right panel); *P < .05. (D) Western blot analysis for
CD44 in SKOV3 cells transiently transfected with siRNA control or targeting CD44 (left panel). qRT-PCR quantifies E-cadherin expression
in SKOV3 cells transiently transfected with siRNA control or targeting CD44 (right panel) and treated with rTG2 for 72 hours. Y axis
represents fold change in E-cadherin level normalized to GAPDH; *P < .05; NS, not significant. (E) qRT-PCR quantifies expression levels
for CD44 normalized to GAPDH in OV90 xenografts from animals treated with control and rTG2 (n = 3 per group, right panel). Y axis
represents fold change in CD44 expression; *P < .05.
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transforming growth factor–β, interleukin-12 (IL-12), and macrophage
response [38]. That deregulated immune response could contribute to
altered immune tolerance, which may promote tumor formation.
We previously showed that cellular TG2 enhances metastasis and
induces EMT [17,39]. The current observations highlight a new path-
way through which extracellular TG2 activates NF-κB, induces CD44,
and promotes EMT and metastasis. We demonstrate that the two TG2
compartments have distinct effects on the NF-κB complex. While
intracellular TG2 activates NF-κB through an IκBα degradation–
dependent mechanism [7], extracellular TG2 activates IKKα leading
to induction of gene transcription through the p52/RelB complex
[40]. Furthermore, by demonstrating that the catalytically inactive en-
zyme fails to induce phosphorylation of IKKα, p65, or p100, we show
that the enzymatic function of TG2 is important in this process. This is
particularly important as TGase activity is enhanced in the extracellular
milieu, where Ca2+ is abundant and GTP concentrations are low.
Remaining yet undefined is how extracellular TG2 initiates non-
canonical NF-κB signaling. The engagement of a limited subset of
tumor necrosis factor superfamily receptors has been implicated in
stabilization of NF-κB inducing kinase (NIK), which activates the non-
canonical pathway [41]. These receptors include CD40, RANK, Fn14,
B-cell activating factor receptor, and lymphotoxin β receptor and are
relevant to B- and dendritic cells’ development [40]. Recent reports
suggest that this pathway is also activated in osteoclasts, mammary
glands, and epithelial cancer cells. Overexpression of Fn14, the receptor
for TNF-related weak inducer of apoptosis (TWEAK), has been
reported in aggressive breast cancer, glioblastoma, and other cancers
[42,43]. Future work will attempt to dissect whether extracellular TG2
engages noncanonical NF-κB signaling directly or indirectly.
Although we had first hypothesized that extracellular TG2 might
facilitate cell adhesion to the ECM, based on the knowledge that
membrane-bound TG2 stabilizes the β1-integrin/FN complex [2,8,25],
our current findings support only a limited role in this process. OC
cell adhesion to FN, VN, or collagen was not enhanced by rTG2 in
the media. However, OC cells’ adhesion to a TG2-primed FN matrix
was increased through an α5β1-integrin–dependent mechanism, an
observation consistent with previous findings implicating syndecan 4
and β1-integrin co-signaling in adhesion to TG2-bound FN [42,43].
Therefore, our study suggests that in the peritoneal milieu, TG2 cross-
linked matrix may provide a more suitable substrate for OC cells. Ad-
ditionally, we found that extracellular TG2 robustly induces CD44
expression in OC cells and xenografts through an RelB-dependent
mechanism. As CD44 mediates cell adhesion to the mesothelium
[44], it is possible that by upregulating this receptor, extracellular
TG2 could also positively alter cancer cells’ interaction with the peri-
toneal surface. By interacting with cytoskeletal proteins, CD44 has also
been linked to EMT [29,30] and here we show that CD44 induction
by rTG2 is involved in NF-κB–mediated EMT.
In summary, our in vitro and in vivo data support that extracellular
TG2 promotes tumor metastasis by increasing adhesion to a TG2-
primed matrix and by activating noncanonical NF-κB, which in turn
promotes EMT and cell invasiveness. A model supporting the func-
tions of TG2 in the intracellular and extracellular space is presented
in Figure 7. Taken together, our data support that TG2 acts as a
metastasis enhancer at the cancer cell–matrix interface.
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Supplementary Materials
Materials and Methods
Expression and purification of human TG2. Full-length and
catalytically inactive (C277A) TG2 were expressed in E. coli and
purified as described [6], with minor modifications. Briefly, overnight
cultures from E. coli BL21 cells (Invitrogen, Grand Island, NY) trans-
formed with pET28-TG2 expression vector (gift from Dr E. A.
Cerione) were grown at 37°C. Protein expression was induced with
300 μM isopropylthio-β-galactoside (IPTG) for 24 hours at 25°C.
Cell pellets were lysed by sonication at 0°C in lysis buffer [50 mM
Na2HPO4 (pH 7.5), 400 mM NaCl, 5 mM benzamidine, and 5 mM
2-mercaptoethanol] containing 50 μM GTP, 50 μM adenosine-5′-
triphosphate (ATP), and 50 μg/ml phenylmethanesulfonyl fluoride
(PMSF). After sonication, NP-40 was added to a concentration of
0.5% (vol/vol). Cell debris was removed by high-speed centrifugation
and the supernatantwasmixedwithTalonmetal affinity resins (Clontech,
Mountain View, CA). The His6-TG2 fusion protein was eluted with
50 mM Hepes (pH 7.0), 50 mM NaCl, 5 mM 2-mercaptoethanol,
20 μM guanosine diphosphate (GDP), and 160 mM imidazole. The
eluted protein was dialyzed against 50 mM MES (pH 6.5), 50 mM
NaCl, 10% (vol/vol) glycerol, 1 mM EDTA, and 5 mM DTT and
loaded onto a MonoQ anion exchange column (Clontech). rTG2
was eluted by using a gradient of 50 to 450 mM NaCl in MES buffer.
The fractions containing rTG2 were pooled and concentrated. Purity
of rTG2 was confirmed by SDS-PAGE, and transamidation activity
was assayed using a colorimetric kit (Sigma; No. CS1070), according
to the manufacturer’s instructions.
Cell proliferation. Cells were seeded in 96-well plates at a density of
2 × 104 cells/well and allowed to proliferate from 1 to 7 days in medium
containing 1% or 10% FBS. Cell proliferation was measured by using
the BrdU proliferation assay (Roche Molecular Biochemicals, Mann-
heim, Germany) following the manufacturer’s directions. Absorbance
values were read using the Ultra Multifunctional Microplate Reader
(Tecan, Durham, NC). Data shown are means ± SE of four replicates.
Clonogenic assay. Cells were seeded at a concentration of 100 cells/
six-well plate and allowed to proliferate in medium containing 1% or
10% FBS over a 2-week period. Colonies were fixed with methanol–
acetic acid (3:1), stained with Hema3 (Fisher Diagnostics, Middle-
town, VA), and counted. Data represent means ± SE of three replicates.
Results
Table W1. Estimated TG2 Concentrations in OC Ascites (see Figure 1B).
Sample No. Estimated TG2 Concentration (μg/ml)
1 ∼6
2 ∼0.8
9 ∼0.8
10 ∼0.3
11 ∼0.1
12 ∼0.8
13 ∼10
20 ∼0.3
21 ∼1
22 ∼1.7
Figure W1. Purified rTG2. (A) Purified protein samples were ran on SDS-PAGE and stained with Coomassie brilliant blue (left panel): lane 1,
protein standard; lane 2, commercially purified TG2 (Sigma); lane 3, recombinant purified His6-TG2 (rTG2). Western blot analysis for TG2
(right panel): lane 5, commercially purified TG2; lane 6, rTG2; lane 7, C277A TG2 mutant. (B) TG2 enzymatic activity for rTG2, C277A
mutant, and commercial TG2.
Figure W2. Effects of intracellular TG2 overexpression on cancer cell proliferation. (A and B) BrdU assay measures cell proliferation of
OV90-TG2 and control cells grown in normal (10% FBS; A) or low serum (1% FBS; B) conditions. Bars represent averages of four rep-
licates ± SE. The experiment was repeated with similar results. (C) Clonogenic assay measured number of colonies generated from
OV90-TG2 and control cells grown in normal (10% FBS) or low serum (1% FBS) conditions. Bars represent average number of colonies
in three replicates ± SE. (D and E) BrdU assay measures cell proliferation of OV90 cells grown in normal (10% FBS; D) or low serum (1%
FBS; E) conditions and treated with buffer or rTG2 (1 μg/ml). Bars represent averages of four replicates ± SE. The experiment was
repeated with similar results.
